Skip to main content

Dr. Andrew S. Bomback, M.D.

Nephrology (Kidney) (Nephrology Physician)

  • Medicare participating

At a glance

Years since graduation
23
In the NPI registry since
2007
Medicare patients seen, 2024
208

The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is

Education and training

  • 2003Medical school: Columbia University College of Physicians and Surgeons
  • 2007Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier

Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).

Specialties and state licenses

  • Nephrology Physician primary
    NY license 251905

As reported to the NPI registry. To confirm a license is current, check the state medical board.

Map: Nephrology (Kidney) per capita by county →

Where they work

Hospitals

Medical groups

Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.

Medicare patients and services

Medicare patients, 2024
208
Services billed
666
Patients’ average age
70
Most frequent Medicare services, 2023
ServiceTimesPatients
Established patient office or other outpatient visit, 40-54 minutes17592
Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes15772
Critical care, first 30-74 minutes5611
Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes4822
Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes3232
New patient office or other outpatient visit, 60-74 minutes2525
Insertion of needle into vein for collection of blood sample2018
Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes1515

Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.

Medicare prescriptions

Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.

Payments from drug and device companies

In 2025, 11 companies reported 22 payments worth $27,416 in total to this clinician.

By type
Consulting Fee$24,527
Honoraria$2,100
Food and Beverage$789

What the payments were for

Largest payments other than meals
DateCompanyWhat it was forAmount
Jun 20, 2025Apellis Pharmaceuticals, Inc.
Jun 20, 2025
Consulting Fee$4,602
Dec 15, 2025GlaxoSmithKline, LLC.
Dec 15, 2025
Consulting Fee$3,250
Jul 29, 2025Novartis Pharma AG
Jul 29, 2025
Consulting Fee
Fabhalta · Immunology
$2,925
May 19, 2025Otsuka Pharmaceutical Development & Commercialization, Inc.
May 19, 2025
Consulting Fee$2,628
May 19, 2025Otsuka Pharmaceutical Development & Commercialization, Inc.
May 19, 2025
Consulting Fee$2,190
May 19, 2025Otsuka Pharmaceutical Development & Commercialization, Inc.
May 19, 2025
Consulting Fee$2,190
Nov 7, 2025Otsuka Pharmaceutical Development & Commercialization, Inc.
Nov 7, 2025
Consulting Fee$2,190
May 29, 2025Ani Pharmaceuticals, Inc.
May 29, 2025
Honoraria
ILUVIEN · treatment of diabetic macular edema in patients who have been previously treated
$2,100
Nov 7, 2025Otsuka Pharmaceutical Development & Commercialization, Inc.
Nov 7, 2025
Consulting Fee$1,460
May 19, 2025Otsuka Pharmaceutical Development & Commercialization, Inc.
May 19, 2025
Consulting Fee$1,314
All 13 payments other than meals, newest first
All payments other than meals
DateCompanyWhat it was forAmount
Dec 15, 2025GlaxoSmithKline, LLC.
Dec 15, 2025
Consulting Fee$3,250
Nov 7, 2025Otsuka Pharmaceutical Development & Commercialization, Inc.
Nov 7, 2025
Consulting Fee$2,190
Nov 7, 2025Otsuka Pharmaceutical Development & Commercialization, Inc.
Nov 7, 2025
Consulting Fee$1,460
Oct 22, 2025Novartis Pharmaceuticals Corporation
Oct 22, 2025
Consulting Fee
Fabhalta · Immunology
$650
Aug 4, 2025Apellis Pharmaceuticals, Inc.
Aug 4, 2025
Consulting Fee$398
Jul 29, 2025Novartis Pharma AG
Jul 29, 2025
Consulting Fee
Fabhalta · Immunology
$2,925
Jun 20, 2025Apellis Pharmaceuticals, Inc.
Jun 20, 2025
Consulting Fee$4,602
May 29, 2025Ani Pharmaceuticals, Inc.
May 29, 2025
Honoraria
ILUVIEN · treatment of diabetic macular edema in patients who have been previously treated
$2,100
May 19, 2025Otsuka Pharmaceutical Development & Commercialization, Inc.
May 19, 2025
Consulting Fee$2,628
May 19, 2025Otsuka Pharmaceutical Development & Commercialization, Inc.
May 19, 2025
Consulting Fee$2,190
May 19, 2025Otsuka Pharmaceutical Development & Commercialization, Inc.
May 19, 2025
Consulting Fee$2,190
May 19, 2025Otsuka Pharmaceutical Development & Commercialization, Inc.
May 19, 2025
Consulting Fee$1,314
May 19, 2025Otsuka Pharmaceutical Development & Commercialization, Inc.
May 19, 2025
Consulting Fee$730

Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.

From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.

Who received the most in New York →

Industry-funded research

Named as a principal investigator on 4 industry-funded studies in 2025, from 2 companies. The companies reported $817,401 in research payments for these studies, mostly to the institutions running them.

  • An open-label, non-randomized extension study to evaluate the long-term efficacy, safety and tolerability of LNP023 in subjects with C3 glomerulopathy
    Novartis Pharmaceuticals Corporation
  • Gazyva for the treatment of MN
    Genentech, Inc.
  • A Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled Study to Evaluate the Efficacy and Safety of Iptacopan (LNP023) in Idiopathic Immune Complex Mediated Membranoproliferative Glomerulonephriti…
    Novartis Pharmaceuticals Corporation
  • A Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled Study to Evaluate the Efficacy and Safety of Iptacopan (LNP023) in Complement 3 Glomerulopathy
    Novartis Pharmaceuticals Corporation

From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.

Other Nephrology (Kidney) clinicians in New York

Sources

NPI registry (CMS NPPES, November 2026; record last updated August 24, 2011), Medicare Care Compare, Medicare Physician & Other Practitioners (2024), Medicare Part D Prescribers (2024) and Open Payments (2025). Information is self-reported or billed data and may be out of date; call before visiting.

NPI 1013129816. Official NPI registry record (opens in a new tab). Clinicians can correct their information in NPPES; changes appear here after our next monthly update.